Stem cells, exosomes, gene therapy, peptides, hyperbaric oxygen, and epigenetic reprogramming
390 articles
Researchers used AI protein design to rebuild prime editor enzymes, achieving up to 2.9-fold better genome editing in mice.
Harvard researchers identify a rare mesenchymal cell type that regenerates the thymus and boosts T cell immunity in aged animals.
A newly discovered immune pathway suppresses thymic regeneration post-damage — and blocking IL-18 may restore it.
Kyoto researchers built the first fully in vitro system that guides stem cells through every stage of human thymus development, producing functional T cells.
Researchers engineer tissue-targeting lipid nanoparticles that precisely deliver mRNA and prime editing tools to lungs, liver, spleen, thymus, and bone.
Computational protein design produces potent GPCR-targeting miniproteins for pain, cancer, obesity, and migraine with in vivo efficacy.
Wave Life Sciences shares early trial data on an RNA editing treatment for alpha-1 antitrypsin deficiency, targeting monthly dosing.
A second wave of RAS-targeting therapies is reshaping cancer treatment, with implications for longevity through better tumor control.
A comprehensive review of pathophysiology, genetics, and emerging therapies for mitochondrial myopathies, spotlighting elamipretide and gene therapy.
A phase 2b trial finds allogeneic MSC infusions improved 6-minute walk distance by 63 meters vs placebo at 9 months in frail older adults.
AstraZeneca's baxdrostat wins FDA approval for hypertension, offering a novel mechanism for patients uncontrolled on existing therapies.
A Phase 2 trial evaluates MBA-P01, a novel botulinum toxin A, for safety and optimal dosing in treating frown lines.
